Clinical trials: Neoplasms by Site
Metastatic Castration-resistant Prostate Cancer
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC.
- Trial name
- VECTRA-01 (NCT07611110)
- Testing
- Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]), Cabazitaxel, Abiraterone
- Where
- 151 sites in United States, Australia and 22 more
- Volunteers
- 670 people
- Sponsor
- AstraZeneca
Esophageal Squamous Cell Carcinoma
Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)
To study the safety and efficacy of the combination of LJM716 and BYL719 against currently available treatments of physician's choice in previously treated esophageal squamous cell carcinoma patients.
- Trial name
- NCT01822613
- Testing
- LJM716, BYL719, Paclitaxel
- Where
- 13 sites in United States, Belgium and 7 more
- Volunteers
- 48 people
- Sponsor
- Novartis Pharmaceuticals
Colorectal Cancer, Head and Neck Cancer
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
The purpose of the study is to determine the safety, tolerability and maximum tolerated dose of Urelumab in combination with Cetuximab in patients with Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell…
- Trial name
- NCT02110082
- Testing
- Urelumab, Cetuximab
- Where
- 7 sites in United States
- Volunteers
- 66 people
- Sponsor
- Bristol-Myers Squibb
Non-small Cell Lung Cancer
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
The purpose of this two-stage phase II study is to assess the efficacy of BKM120, as measured by determining the progression free survival (PFS), in patients with pretreated metastatic Non-small Cell Lung Cancer (NSCLC) that…
- Trial name
- BASALT-1 (NCT01297491)
- Testing
- BKM120
- Where
- 92 sites in United States, Argentina and 16 more
- Volunteers
- 63 people
- Sponsor
- Novartis Pharmaceuticals
Breast Tumors, Wound Healing
HealiAid Collagen Wound Dressing in Patients Undergoing Breast Tumor Surgery
The goal of this clinical trial is to evaluate the safety of the collagen wound dressing (HealiAid) in breast tumor patients with surgical treatment. The main questions it aims to answer are: 1.
- Conditions
- Breast Tumors, Wound Healing, Collagen Wound Dressing
- Trial name
- NCT07209020
- Testing
- HealiAid Collagen Wound Dressing
- Where
- 3 sites in Taiwan
- Volunteers
- 60 people
- Sponsor
- Maxigen Biotech Inc.
Non-Small Cell Lung Cancer, Renal Cell Carcinoma
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
The purpose of this study is to evaluate participant preference for coformulated hyaluronidase/pembrolizumab pembrolizumab (+) berahyaluronidase alfa [MK-3475A] administered subcutaneously (SC) over pembrolizumab [MK-3475]…
- Conditions
- Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma
- Trial name
- NCT06099782
- Testing
- Pembrolizumab (+) Berahyaluronidase alfa, Pembrolizumab
- Where
- 45 sites in United States, Argentina and 8 more
- Volunteers
- 147 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Renal Cell
A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)
This clinical study is being conducted at multiple sites to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in papillary renal cell carcinoma.
- Trial name
- NCT00726323
- Testing
- foretinib (formerly GSK1363089 or XL880)
- Where
- 12 sites in United States
- Volunteers
- 74 people
- Sponsor
- GlaxoSmithKline
High Risk Prostate Carcinoma, Biochemically Recurrent Prostate Carcinoma
Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System
This study is designed to evaluate the presence and numbers of circulating tumor cells (CTCs) and cancer related gene expression levels in subjects with localized high-risk prostate cancer (HRLPC) and from subjects with…
- Conditions
- High Risk Prostate Carcinoma, Biochemically Recurrent Prostate Carcinoma, Castration-resistant Prostate Cancer, Prostate Cancer
- Trial name
- CHARTER (NCT05437679)
- Testing
- Blood collection
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Angle plc
Advanced Solid Tumor
A Study of hSTC810 With Advanced/Metastatic Solid Tumors (STCUBE-001)
The Purpose of this study is to investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of hSTC810 monotherapy in participants with advanced solid tumors.
- Trial name
- NCT05231746
- Testing
- hSTC810
- Where
- 5 sites in United States, South Korea
- Volunteers
- 47 people
- Sponsor
- STCube, Inc.
Unresectable or Metastatic Melanoma
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
The purpose of the study is to estimate the response rate and compare overall survival of patients taking BMS-936558 to those taking study physician's choice of either Dacarbazine or Carboplatin and Paclitaxel
- Trial name
- NCT01721746
- Testing
- BMS-936558, Dacarbazine, Carboplatin
- Where
- 95 sites in United States, Austria and 12 more
- Volunteers
- 405 people
- Sponsor
- Bristol-Myers Squibb
Solid Tumors, GI Cancer
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
This is a multicenter, open-label study conducted in two phases: Phase 1 consisting of a CGX1321 Single Agent Dose Escalation Phase in solid tumors, CGX1321 Single Agent Dose Expansion Phase in GI tumors and Roll-over Cohort of…
- Trial name
- NCT02675946
- Testing
- CGX1321, Pembrolizumab, encorafenib
- Where
- 26 sites in United States, Taiwan
- Volunteers
- 72 people
- Sponsor
- Curegenix Inc.
Prostate Cancer
Exploratory PK and Imaging Study of PSMA-Targeted Trillium Compounds and PTI-122 in Metastatic Prostate Cancer
Exploratory study in adult males with metastatic prostate cancer intended to characterize the pharmacokinetics and biodistribution of PSMA-Targeted [In-111]-Labeled Trillium Compounds with and without the cytoprotective agent…
- Trial name
- NCT05773703
- Testing
- PSMA-Targeted [In-111]-Labeled Trillium Compound, PTI-122
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Ratio Therapeutics, Inc.
Stage III or Stage IV Melanoma
Safety Study of CADI-05 in Patients With Advanced Stage Melanoma
This study examines the safety of treating patients with advanced stage melanoma with the vaccine CADI-05. In addition, preliminary data regarding the clinical response and immune response will be collected.
- Trial name
- NCT00675727
- Testing
- CADI-05
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cadila Pharnmaceuticals
Carcinoma, Non-Small-Cell Lung
Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
The purpose of this study is to determine whether the combination therapy of CC-486 (oral azacitidine) and pembrolizumab provides improved patient outcomes compared to pembrolizumab alone in patients with previously treated…
- Trial name
- NCT02546986
- Testing
- CC-486, Pembrolizumab
- Where
- 33 sites in United States, France and 4 more
- Volunteers
- 100 people
- Sponsor
- Celgene
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
This research trial is testing a combination of two experimental drugs, MSC1936369B (Mitogen-activated protein extracellular signal-regulated kinase (MEK) Inhibitor) and SAR245409 (Phosphatidylinositol 3-kinase (Pi3K)/Mammalian…
- Conditions
- Locally Advanced Solid Tumor, Metastatic Solid Tumor, Breast Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT01390818
- Testing
- MSC1936369B (pimasertib), SAR245409 (PI3K and mTOR inhibitor)
- Where
- 8 sites in United States, Italy and 1 more
- Volunteers
- 146 people
- Sponsor
- EMD Serono
Hepatocellular Carcinoma, Biliary Tract Cancer
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
GEMINI-Hepatobiliary study will assess the efficacy, safety and tolerability of novel immunomodulators alone and in combination with other anticancer drugs in participants with specified advanced solid tumors.
- Trial name
- NCT05775159
- Testing
- Volrustomig, Bevacizumab, Lenvatinib
- Where
- 46 sites in United States, China and 7 more
- Volunteers
- 294 people
- Sponsor
- AstraZeneca
Prostate Cancer
A Post-marketing Surveillance to Assess Safety of Abiraterone Acetate (Zytiga) in Indian Participants With Metastatic, Castration Resistant Prostate Cancer
The purpose of this study is to evaluate the safety of abiraterone acetate in Indian participants with metastatic, castration-resistant prostate cancer who have been prescribed abiraterone acetate as per locally approved…
- Trial name
- NCT02608359
- Testing
- Abiraterone Acetate
- Where
- 3 sites in India
- Sponsor
- Johnson & Johnson Private Limited
Breast Cancer
Study of ExAblate Focused Ultrasound Ablation of Breast Cancer
The goal of this prospective, non-randomized, single-arm, multi site, international study is to develop data to evaluate the safety and effectiveness of the ExAblate MRgFUS system in the ablation of breast cancer and of MRI.
- Trial name
- NCT01620359
- Testing
- ExAblate MRgFUS
- Where
- Germany
- Volunteers
- 14 people
- Sponsor
- InSightec
Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed…
- Conditions
- Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer
- Trial name
- NCT06047379
- Testing
- NEO212 Oral Capsule, Ipilimumab, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 134 people
- Sponsor
- Neonc Technologies, Inc.
Breast Cancer
A Trial of Gemcitabine Combined With Vinorelbine as First Line Chemotherapy for Metastatic Breast Cancer
This is a Phase II study of gemcitabine- Vinorelbine combination in a 3-weekly schedule as first line chemotherapy in patients with metastatic breast cancer. Eighty patients with measurable disease will be enrolled in the study.
- Trial name
- NCT00192062
- Testing
- gemcitabine, vinorelbine
- Where
- 4 sites in Egypt
- Volunteers
- 80 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.